Trial
NCT01958112
GSK1120212+GSK2141795 for Cervical Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Novartis; National Comprehensive Cancer Network
Condition
Cervical Cancer
Intervention
GSK1120212 (trametinib)
Why stopped
Drug supply
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-31